Medicine and Dentistry
Acute Liver Failure
12%
Alanine Aminotransferase
12%
Alcohol Consumption
13%
Alcohol-Related Liver Disease
14%
Alzheimer's Disease
12%
Chronic Kidney Disease
16%
Chronic Liver Disease
24%
Clinical Trial
17%
Cohort Analysis
24%
COVID-19
24%
Decompensated Liver Cirrhosis
37%
Dexamethasone
12%
Diabetes
13%
Disease
35%
Disease Management
18%
Fatty Liver
24%
Fibrosis
59%
Frailty
14%
Hepatitis B
33%
Hepatitis C
24%
Hepatocellular Carcinoma
12%
Hepatology
65%
Infection
19%
Ingestion
16%
Liver Cirrhosis
55%
Liver Disease
100%
Liver Fibrosis
20%
Liver Function
31%
Liver Transplantation
24%
Macrophage
24%
Maturity Onset Diabetes of the Young
14%
Medicine
22%
Metabolic Dysfunction-Associated Steatotic Liver Disease
79%
Model for End-Stage Liver Disease
17%
Neuro-Oncology
12%
Nonalcoholic Fatty Liver
61%
Nutrition
18%
Odontoid Process Fracture
12%
Patient Referral
12%
Physical Activity
18%
Prevalence
27%
Primary Health Care
15%
Public Health
21%
Randomized Controlled Trial
36%
Retrospective Study
29%
Specialist Care
13%
Steatohepatitis
15%
Subdural Hematoma
12%
Systematic Review
36%
Transplantation
12%
Keyphrases
Advanced Liver Disease
13%
Antifibrotic
16%
British Association
26%
British Society
13%
Care Delivery
14%
Chronic Infection
13%
Chronic Kidney Disease
18%
Cirrhosis
35%
Clinical Practice Guidelines
16%
Decompensated Cirrhosis
40%
Diabetes
13%
Disease Management
24%
Etiology
19%
Fatty Liver Disease
24%
Fibrosis
33%
Fibrosis Assessment
13%
Hepatitis B
24%
Hepatitis C
24%
Hepatocellular Carcinoma
22%
Hepatology
58%
Interleukin-2
22%
Liver
51%
Liver Cirrhosis
34%
Liver Disease
58%
Liver Function Tests
25%
Liver Transplantation
12%
Liver Type
12%
Macrophage Therapy
24%
MELD Score
24%
Metabolic-associated Fatty Liver Disease (MAFLD)
91%
Multicenter Retrospective Study
24%
Narrative Review
13%
Non-alcoholic Fatty Liver Disease (NAFLD)
61%
Nonalcoholic Steatohepatitis
36%
Older Adults
25%
Phase 2 Randomized Controlled Trial
14%
Phosphoinositide 3-kinase (PI3K)
36%
Phosphorylation
13%
Physical Activity
15%
Randomized Controlled Trial
24%
Rapamycin
14%
S6 Kinase 1 (S6K1)
13%
Scotland
47%
Scottish
28%
Soluble interleukin-2 Receptor (sIL-2R)
13%
Specialty Care
13%
Steatotic Liver Disease
24%
T Cells
27%
Tayside
13%
Type 2 Diabetes Mellitus (T2DM)
15%